GRAIL, Inc.
GRALHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. With a market capitalization of $5.92B, it sits in mid-cap territory. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Market Cap
$5.92B
Beta
2.84
P/E (TTM)
—
P/E (Fwd)
-16.07
EPS (TTM)
$-9.70
EPS (Fwd)
$-8.25
ROE
-16.1%
ROA
-12.0%
Cash
$861.6M
Total Debt
$91.3M
Free CF
-$103.6M
52W Change
55.9%
Annual Financials
Cash vs Debt
Where GRAL stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, GRAL finished 93.65% above its 150-day moving average ($72.14) and 84.67% above its 200-day moving average ($75.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRAL overbought or oversold?
At the October 15, 2026 close, GRAL's RSI(14) was 59.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $861.6M in cash and $91.3M in debt, GRAL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$103.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -16.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $55.5M (2022) to $147.2M (2025), reflecting a 165% increase over the period.
A beta of 2.84 means GRAL is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, GRAL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GRAIL, Inc.'s trajectory.